Monoamine oxidase is a mitochondrial outermembrane flavoenzyme that is a target for antidepressant and neuroprotective drugs.
Application
Monoamine Oxidase inhibitors (MAOIs) are used to treat mental disorders including depression and Parkinson′s. [1]
This product is suitable as a negative control for MAO-A and MAO-B.
Biochem/physiol Actions
Monoamine Oxidase (MAO) is an integral flavoprotein of the outer mitochondrial membrane. MAOs are responsible for catalyzing the oxidative deamination of a wide variety of xenobiotic and endobiotic primary, secondary, and tertiary amines. The primary endogenous function of MAOs involves the inactivation of monoamine neurotransmitters, such as serotonin and dopamine. MAOs exist in two isoforms, MAO-A and MAO-B, which share approximately 70% sequence identity on the amino acid level.1 Both isoforms are nearly ubiquitous in mammals, but show particularly high enzymatic activity in the central nervous system and liver.
Cleveland Clinic journal of medicine, 77(12), 859-882 (2010-12-15)
Monoamine oxidase (MAO) inhibitors were the first antidepressants introduced, but their use has dwindled because of their reported side effects, their food and drug interactions, and the introduction of other classes of agents. However, interest in MAO inhibitors is reviving.
Fundamental & clinical pharmacology, 15(2), 75-84 (2001-07-27)
Although the cytochrome P450 (CYP) system ranks first in terms of catalytic versatility and the wide range of xenobiotics it detoxifies or activates to reactive intermediates, the contribution of amine oxidases and in particular of monoamine oxidases (MAOs) to the
Identification, cellular localization, and cDNA cloning of MAO subtypes A and B have increased the insight into the pharmacology of these enzymes, whose primary functions are intra- and extraneuronal inactivation of neurotransmitter (dopamine, noradrenaline and serotonin) and other biogenic amines.
Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors.
A S Kalgutkar et al.
Chemical research in toxicology, 14(9), 1139-1162 (2001-09-18)
European journal of nuclear medicine and molecular imaging, 49(11), 3797-3808 (2022-05-22)
[18F]-labeled positron emission tomography (PET) radioligands permit in vivo assessment of Alzheimer's disease biomarkers, including aggregated neurofibrillary tau (NFT) with [18F]flortaucipir. Due to structural similarities of flortaucipir with some monoamine oxidase A (MAO-A) inhibitors, this study aimed to evaluate flortaucipir
Questions
Reviews
★★★★★ No rating value
Active Filters
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.